dc.creatorArmeno, Marisa
dc.creatorCaraballo, Roberto Horacio
dc.date.accessioned2022-09-23T12:03:22Z
dc.date.accessioned2022-10-15T16:39:14Z
dc.date.available2022-09-23T12:03:22Z
dc.date.available2022-10-15T16:39:14Z
dc.date.created2022-09-23T12:03:22Z
dc.date.issued2020-07
dc.identifierArmeno, Marisa; Caraballo, Roberto Horacio; The evolving indications of KD therapy; Elsevier Science; Epilepsy Research; 163; 106340; 7-2020; 1-8
dc.identifier0920-1211
dc.identifierhttp://hdl.handle.net/11336/170146
dc.identifier1872-6844
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4410335
dc.description.abstractDespite the rapid increase of clinical and basic-science knowledge on ketogenic diet therapies over the past years, it has not always been easy to determine the adequate indications of this treatment. Over the nearly 100 years of use, from being a last resource in the therapeutic algorithm, the diet has become one of the four main treatments for patients with difficult-to-control epilepsy together with antiepileptic drugs, surgery, and vagus nerve stimulation. The use of the diet has also changed. The current paper will briefly discuss the history of the diet together with a review of the literature regarding its most important indications and how they have evolved. The concept of the importance of defining the type of seizure, type of syndrome, and etiology in the selection of patients and timing of diet initiation has been gaining importance. This paper explores how the indications of the diet changed together with the shifting focus of epilepsy teams towards its use in different types of epilepsy and epilepsy syndromes and according to etiologies and as an alternative option in refractory and superrefractory status epilepticus.
dc.languageeng
dc.publisherElsevier Science
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.eplepsyres.2020.106340
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0920121120301017
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectEPILEPTIC ENCEPHALOPATIES
dc.subjectINDICATIONS
dc.subjectKETOGENIC DIET
dc.subjectREFRACTORY EPILEPSY
dc.subjectSTATUS
dc.titleThe evolving indications of KD therapy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución